IR@PKUHSC  > 北京大学第一临床医学院  > 感染疾病科
学科主题临床医学
Hepatitis B surface antigen seroconversion after HBV reactivation in non-Hodgkin′s lymphoma
Liu, Wei-Ping1; Zheng, Wen1; Song, Yu-Qin1; Ping, Ling-Yan1; Wang, Gui-Qiang2; Zhu, Jun1
关键词Hepatitis b Surface Antigen Seroconversion Non-hodgkin&Prime s Lymphoma Rituximab Entecavir
刊名WORLD JOURNAL OF GASTROENTEROLOGY
2014-05-07
DOI10.3748/wjg.v20.i17.5165
20期:17页:5165-5170
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Gastroenterology & Hepatology
资助者National Natural Science Foundation of China ; Peking University Cancer Hospital Foundation for Scientific Research ; National Natural Science Foundation of China ; Peking University Cancer Hospital Foundation for Scientific Research
研究领域[WOS]Gastroenterology & Hepatology
关键词[WOS]VIRUS REACTIVATION ; CELL LYMPHOMA ; RITUXIMAB ; CHEMOTHERAPY ; ENTECAVIR ; INFECTION ; PATIENT ; TRIAL ; POLYCHEMOTHERAPY ; METAANALYSIS
英文摘要

Reactivation of hepatitis B virus (HBV) can occur in lymphoma patients infected with HBV when they receive chemotherapy or immunotherapy. Prophylactic administration of lamivudine (LAM) reduces the morbidity and mortality associated with HBV reactivation. However, what defines HBV reactivation and the optimal duration of treatment with LAM have not yet been clearly established. HBV reactivation may occur due to the cessation of prophylactic LAM, although re-treatment with nucleoside analogs may sometimes result in hepatitis B surface antigen (HBsAg) seroconversion, which is a satisfactory endpoint for the management of HBV infection. We report a case of HBV reactivation in a 68-year-old HBsAg-positive patient who received rituximab-based immunochemotherapy for follicular lymphoma. HBV reactivation developed following cessation of prophylactic LAM therapy. The patient subsequently received treatment with entecavir (ETV), which led to a rapid and sustained suppression of HBV replication and HBsAg seroconversion. We also appraised the literature concerning HBV reactivation and the role of ETV in the management of HBV reactivation in lymphoma patients. A total of 28 cases of HBV reactivation have been reported as having been treated with ETV during or after immunosuppressive chemotherapy in lymphoma patients. We conclude that ETV is an efficacious and safe treatment for HBV reactivation following LAM cessation in lymphoma patients treated with rituximab-based immunochemotherapy. (C) 2014 Baishideng Publishing Group Co., Limited. All rights reserved.

语种英语
所属项目编号81241073 ; 2013-Autonomous-9
资助者National Natural Science Foundation of China ; Peking University Cancer Hospital Foundation for Scientific Research ; National Natural Science Foundation of China ; Peking University Cancer Hospital Foundation for Scientific Research
WOS记录号WOS:000335916700044
引用统计
被引频次:8[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/56131
专题北京大学第一临床医学院_感染疾病科
作者单位1.Peking Univ, Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res, Dept Lymphoma,Minist Educ, Beijing 100142, Peoples R China
2.Peking Univ, Dept Infect Dis, Ctr Liver Dis, Hosp 1, Beijing 100142, Peoples R China
推荐引用方式
GB/T 7714
Liu, Wei-Ping,Zheng, Wen,Song, Yu-Qin,et al. Hepatitis B surface antigen seroconversion after HBV reactivation in non-Hodgkin′s lymphoma[J]. WORLD JOURNAL OF GASTROENTEROLOGY,2014,20(17):5165-5170.
APA Liu, Wei-Ping,Zheng, Wen,Song, Yu-Qin,Ping, Ling-Yan,Wang, Gui-Qiang,&Zhu, Jun.(2014).Hepatitis B surface antigen seroconversion after HBV reactivation in non-Hodgkin′s lymphoma.WORLD JOURNAL OF GASTROENTEROLOGY,20(17),5165-5170.
MLA Liu, Wei-Ping,et al."Hepatitis B surface antigen seroconversion after HBV reactivation in non-Hodgkin′s lymphoma".WORLD JOURNAL OF GASTROENTEROLOGY 20.17(2014):5165-5170.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Liu, Wei-Ping]的文章
[Zheng, Wen]的文章
[Song, Yu-Qin]的文章
百度学术
百度学术中相似的文章
[Liu, Wei-Ping]的文章
[Zheng, Wen]的文章
[Song, Yu-Qin]的文章
必应学术
必应学术中相似的文章
[Liu, Wei-Ping]的文章
[Zheng, Wen]的文章
[Song, Yu-Qin]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。